123 related articles for article (PubMed ID: 8684530)
1. Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
Andriani M; Nordio M; Saporiti E
Nephron; 1996; 72(2):218-24. PubMed ID: 8684530
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
Verpooten GA; D'Haese PC; Boelaert JR; Becaus I; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1992; 7(9):931-8. PubMed ID: 1328941
[TBL] [Abstract][Full Text] [Related]
3. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
[TBL] [Abstract][Full Text] [Related]
4. Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.
Vasilakakis DM; D'Haese PC; Lamberts LV; Lemoniatou E; Digenis PN; De Broe ME
Kidney Int; 1992 May; 41(5):1400-7. PubMed ID: 1614055
[TBL] [Abstract][Full Text] [Related]
5. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
Canavese C; Gurioli L; D'Amicone M; Cardelli R; Caligaris F; Bongiorno P; Arnaud A; Mattiello G; Marchiori M
Nephron; 1992; 60(4):411-7. PubMed ID: 1584315
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis.
Allain P; Chaleil D; Mauras Y; Varin MC; Ang KS; Cam G; Simon P
Clin Chim Acta; 1988 Apr; 173(3):313-6. PubMed ID: 3383431
[TBL] [Abstract][Full Text] [Related]
8. The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients.
Huang JY; Wu MS; Wu CH
Ren Fail; 2001 Nov; 23(6):789-95. PubMed ID: 11777318
[TBL] [Abstract][Full Text] [Related]
9. Desferrioxamine in the treatment of aluminum overload.
Ackrill P; Day JP
Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
Allain P; Chaleil D; Mauras Y; Beaudeau G; Varin MC; Poignet JL; Ciancioni C; Ang KS; Cam G; Simon P
Clin Chim Acta; 1987 Dec; 170(2-3):331-8. PubMed ID: 3436066
[TBL] [Abstract][Full Text] [Related]
11. Indirect measurement of desferrioxamine and its chelated compounds aluminoxamine and ferrioxamine by Zeeman atomic absorption spectrometry.
D'Haese PC; Lamberts LV; De Broe ME
Clin Chem; 1989 May; 35(5):884-7. PubMed ID: 2720988
[TBL] [Abstract][Full Text] [Related]
12. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
[TBL] [Abstract][Full Text] [Related]
13. Improvement of anaemia with desferrioxamine in haemodialysis patients.
Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL
Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265
[TBL] [Abstract][Full Text] [Related]
14. Chromatographic studies of aluminum-desferrioxamine complex in uremic patients.
Canavese C; Pacitti A; Salomone M; Pramotton C; Segoloni G; Bedino S; Testore G; Lamon S; Vercellone A
ASAIO Trans; 1986; 32(1):367-9. PubMed ID: 3778736
[No Abstract] [Full Text] [Related]
15. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients.
Stivelman J; Schulman G; Fosburg M; Lazarus JM; Hakim RM
Kidney Int; 1989 Dec; 36(6):1125-32. PubMed ID: 2601259
[TBL] [Abstract][Full Text] [Related]
16. Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function.
D'Haese PC; Lamberts LV; Verpooten GA; Vaneerdeweg W; Jurgens A; Arakelian S; Babloyan A; Digenis P; Tjalma W; De Broe ME
Kidney Int; 1994 Jan; 45(1):76-84. PubMed ID: 8127024
[TBL] [Abstract][Full Text] [Related]
17. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
[TBL] [Abstract][Full Text] [Related]
18. Estimation of aluminoxamine and ferrioxamine in plasma by high performance liquid chromatography.
Hughes H; Hagen LE; Cameron EC; Sutton RA
Clin Chim Acta; 1986 May; 157(1):115-20. PubMed ID: 3719992
[No Abstract] [Full Text] [Related]
19. Concomitant iron and aluminum mass transfer following deferoxamine infusion during hemofiltration.
Canavese C; Salomone M; Pacitti A; Mangiarotti G; Thea A; Dogliani M; Serra A
Am J Kidney Dis; 1991 Feb; 17(2):179-84. PubMed ID: 1992660
[TBL] [Abstract][Full Text] [Related]
20. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
Jarava C; Armas JR; Palma A
Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
